Mr Vinod Nargund is a Consultant Urological Surgeon at St Bartholomew's and Homerton Hospitals in London. His special interests include Urological cancers, laparosopy and Male factor Infertility. He is also an honorary senior lecturer in Surgical Sciences at Queen Mary Barts and the London School of Medicine and Dentistry University of London.
Qualifications
MBBS (1978), MS (1982): Karnatak University, India
FRCS: Royal College of Surgeons, Edinburgh [1985]
PhD: Bradford University, Bradford [1995]
FRCS (Urol): Intercollegiate Board, Edinburgh [1996]
FEBU: European Board of Urology, Rotterdam [2001]
Mr Nargund was trained in Urological Surgery in Belfast, Bradford and Oxford. Prior to his present post he was Clinical Lecturer in the Nuffield Department of Surgery at the Oxford Radcliffe Hospitals and University of Oxford. He obtained Doctor of Philosophy for his work on bladder cancer. His current research interests include early detection of genito-urinary cancers and patterns of testicular blood flow in infertile patients. His other research interests are angiogenesis and clinical evaluation of blood flow in prostate cancer. He has published papers on bladder, testicular and prostate cancers'. Mr. Nargund has been an examiner for Royal College of Surgeons of England and University of London (both undergraduate and postgraduate).
Publications
Peer-reviewed and commissioned papers (* indicates key publications)
1. Nargund V, Naik KG:Parotid Tumours: Clinico-pathological study. Antiseptic 1981; 32: 93-7
2. Schraibman I G, Micheal Z, Nargund VH, Potdar N: Colonoscopic surveillance after diagnosis of carcinoma of colon and rectum. Annales de Chirurgie 1989; 43(7): 568-9
3.*Nargund VH, Lomas K, Sapherson DA, Flannigan GM, Stewart PA: Radiographer- performed abdominal and pelvic ultrasound: Its value in urology out-patient clinic. British Journal of Urology 1994;73: 366-70
4.Nargund VH, Barker IK, Coombs L, Flannigan GM, Stewart PAH and Crawford SM: Growth characteristics of early passage cell lines compared with established TCC bladder cell lines. Urological Research 1994;22:75-7
5. Nargund VH, Stewart PAH : Point of technique: Endoscopic Localisation of the lesion prior to partial cystectomy. British Journal of Urology 1994; 73(4): 455-6
6. Nargund V H, Hockley I, Flannigan G M: Point of technique: Extracorporeal shock wave lithotripsy for lower ureteric stones through perineal region. British Journal of Urology 1995; 75; 410
7. Nargund V H, Cumming J A, Jerwood D, Sapherson D A, Stewart P A H, Flannigan G M. Ultrasound in urological emergency: results of self audit and implications for training. International Urology and Nephrology1996; 28; 267-71
8.*Sugino T, Gorham H, Yoshida K, Boledeoku J, Goodison S, Nargund V, Cranston D, Tarin D. Progressive loss of Cd44 gene expression in invasive bladder cancer. American Journal of Pathology 1996; 149: 873-82
9. Nargund VH and Cranston D W. Urological complications in renal transplantation. Transplant Reviews 1996; 10: 24-33 (Review)
10.*Yoshida K, Sugino T, Tahara H, Nargund VH, Woodman A, Fellows GJ and Tarin D. Telomerase activity in bladder carcinoma and its implications for non-invasive diagnosis by its detection in exfoliated cancer cells in urine. Cancer 1997; 79: 362-9
11.*Nargund V H, Lowe J, Flanagan G and Hamilton Stewart P. Role of P-Glycoprotein in chemo-resistant superficial bladder tumours. European Urology 1997; 31: 160-2
12.*Robertson AJ, Nargund V, Gray DWR, Morris PJ. Low dose aspirin as prophylaxis against renal vein thrombosis in renal-transplant patients.Nephrology,Dialysis and Transplantation 2000; 15: 1865-8
13. Fenely M, Jan H, Granowska SJ, Mather S, Ellison D, Kirby RS, Oliver RTD, Badenoch DF, Chinegwundoh FC, Nargund VH, Paris AMI, Britton KE. Imaging with prostate specific membrane antigen (PSMA) in prostate cancer. Prostatic carcinoma & Prostatic diseases 2000; 3: 47-52(Review)
14. Nargund V H, Noble J G, Cranston D and Fellows G J. Haematuria: A long-term problem after prostatectomy. Urologia Internationalis 2001; 66: 1-5
15.*Ojha K, Nargund V H, Nargund G. Emergency sperm extraction for transient erectile dysfunction prior to assisted conception. Journal of Assisted Reproduction and Genetics 2001;18: 36-7
16.* Otite U, Webb J A W, Oliver R T D, Badenoch D F and Nargund V H. Testicular microlithiasis: Is it a benign condition with a malignant potential? European Journal of Urology 2001; 40: 538-42
17.* Goonewardene T I, Bozcuk H, Oliver R T, Barua J, Nargund V and Philip T. Phase 1/2 Study of Synchronous Methotrexate, Cisplatin, Vincristine (MOPq10) Chemotherapy and radiation for patients with locally advanced bladder cancer. Urologia Internationalis 2001; 67: 293-7
18 *Sohaib A, Theo J, Nargund VH, Hendry WF, Lumley J, Reznek R. Role of MRI in the evaluation of vena caval involvement of renal cell carcinoma. Journal of Urology2002;167:1271-5
19. Nargund VH. Management of testicular pain. The Practitioner 2002; 246: 792-800
20. Oliver RTD, Ong J, Berney D, Nargund V, Badenoch D and Samash J. Testis conserving chemotherapy in gern cell cancer: Its potential to increase understanding of the biology and treatment of carcinoma in situ. Acta Pathologica Microbiologica et Immunologica Scandanavia 2003:111: 86-91[Meta-analysis]; discussion 91-2
21. Nargund V H. Editorial comment: Flutamide in recurrent prostate cancer. British Journal of Urology International 2003; 92: 698
22.*Oliver R T D, Ong J, Shamash J, Ravi R, Nargund V, Harper P, Ostroveski M J, Sizer B, LeVay J, Robinson A, Neal D E, Williams M. Long-term follow up of Anglian germ cell cancer group surveillance versus patients with stage I non-seminoma treated with adjuvant chemotherapy. Urology 2004; 63: 556-61
23.*Hitchings AW, Kumar M, Jordan S, Nargund V, Martin J, Berney D M. Prediction of progression in pTa and pT1 bladder carcinomas with p53, p16 and pRb. British Journal of Cancer 2004; 91: 552-7
24.*Lucas M, Stephenson T, Nargund VH. Tamsulosin in the management of patients in acute urinary retention due to BPH. British Journal of Urology International 2005; 95: 354-7
25.*Nargund VH, Al-Hashimi D, Kumar P, Gordon S, Otite U, Ellison D, Carroll M, Baithun S, Britton K. Imaging with radio-labelled monoclonal antibody (MUJ 591) to prostate-specific membrane antigen (PSMA) in staging of clinically localised prostatic carcinoma: Comparison with clinical, surgical and histological staging. British Journal of Urology International 2005; 95: 1232-6
26.*Bhardwa JM, Powell R, Berney D, Baithun S, Nargund VH, Oliver RTD. Assessing the size and stage of testicular germ cell tumours 1984-2003. British Journal of Urology International 2005 ; 96:819-21
27. Otite U, Baithun S, Chinegwundoh FC, Nargund VH, Iles RK. Detection of serum and urinary beta human chorionic gonadotrophin (hCGb) in serum or urine is of no clinical significance. Tumor Biology 2006; 27 (4): 181-6
28. Ghani K, Rockall A, Nargund V H, Chinegwundoh F. Comments: Prostate Biopsy: To stop anticoagulation or not? British Journal of Urology International 2006; 97(2): 224-5
29. Kumar P and Nargund V H. Samuel Pepys: A Patient's Perspective of Lithotomy in 17th Century England. Journal of Urology 2006; 175(4): 1221-4 (Review)
30. Kumar P, Kapoor S, Nargund V. Review: Haematospermia. Annals of Royal College of Surgeons of England 2006; 88 (4): 339-42
31. Chinegwundoh FC, Enver MK, Oliver RTD, Nargund VH and Ben-Shlomo Y. Risk and presenting features of prostate cancer amongst African Caribbeans, South Asians and Europeans in Northeast London. British Journal of Urology International 2006; 98:1216-20
32. Kumar P and Nargund VH. Point of technique: Management of post-radical prostatectomy anastomotic stricture by endoscopic transurethral balloon dilatation. Scandinavian Journal of Urology and Nephrology 2007; 41(4):314-5
33. Review- Keeler B, Ghani KR, Nargund VH. Haematuria 1: risk factors, clinical evaluation and laboratory investigations. British Journal of Hospital Medicine 2007; 68(8):418-22
35. Ben-Shlomo Y, Evans S, Ibrahim F, Patel B, Anson K, Chinegwundoh F, Corbishley C, Dorling D, Thomas B, Gillatt D, Kirby R, Muir G, Nargund V, Popert R, Metcalfe C, Persad R on behalf of the PROCESS study group. The risk of prostate cancer amongst Black men in the United Kingdom: The PROCESS retrospective cohort study. European Urology 2007; (In print)
36. Nargund VH, Grey A. Tamsulosin- Pharmacology & Pharmacotherapeutics. Expert Opinion on Pharmacotherapy (in print)
Book/Booklets/Presentations/Proceedings
1.C lonal development of bladder cancer and its relevance to the clinical potential of HLA antigen and p53 based gene therapy. Co-authors: AME Nouri, RTD Oliver. In Cancer Surveys Volume 31: pages 109-128. In Bladder Cancer 1998 Publisher: Imperial Cancer Research Fund 109-128
2. Chemotherapy for testis conservation in patients with germ cell tumours: Is it safe and could combination with tumour enucleation increase the frequency of success? Co-authors: RTD Oliver, D F Badenoch. S A Sohaib, T Lane, J Ong, M Cullen. Germ Cell Tumours V: Proceedings of the 5th International Germ Cell Tumour Conference, University of Leeds. 2001. Editors: P Harnenden, J Joffe and W Jones. Springer, London 2001
3. Medical interventions relevant in prevention and management of early prostate Cancer: a new potential role for GPs, schools and works’ medical officers, as well as STD, family planning and infertility clinics. Co-authors: RTD Oliver, T Lane, P Wells, F Chinegwundoh. In the Effecive Management of Prostate Cancer. Editors: DMA Wallace, RTD Oliver, D Ash and A Miles. Publisher: Aesculapius Medical Press, London 2002
4. Booklet BACUP Series for Cancer Patients: Cancer of the kidney. July 2004
5. Booklet BACUP Series for Cancer Patients: Testicular Cancer. December 2005
6. Testis conserving chemotherapy in germ cell cancer: Its potential to increase understanding of the biology and treatment of carcinoma in situ. Co-authors: Oliver RTD, Ong J, Berney D, Badenoch D, Samash J. p.nos:86-92. In Testicular Germ Cell Neoplasia: A Developmental Disease? Editors: E Rajpert-De Meyts, K M Grigor, N E Skakkabaek. Blackwell-Munksgaard 2003
7. Urological Oncology (2007) Editors: Vinod Nargund, Derek Raghavan (Cleveland) and Howard Sandler (Michigan); Springer UK, London, September 2007; 607pages, 75 illus., 35 in colour ISBN: 978-1-84628-387-1 Chapters written by V Nargund in this book: Haematuria and Haematospermia (Co-author: K Ghani); Testicular Cancer (Co-authors: RTD Oliver & J Shamash); Management of localized prostate cancer; Urethral TCC(Co-author: P.Kumar)
Abstracts and Presentations
1. Colonoscopic Surveillance after Diagnosis of Carcinoma of the Colon and Rectum. Michael Z, Potdar N, Nargund V H, Schraibman I G*. Anglo-French meeting, Hôpital St. Antoine, Paris. November 1988
2. The Development of a Mobile Lithotripsy Service in a NHS Trust Hospital: Flannigan GM*, Stewart P, Nargund V H, Coombs L, Gray B, Doble A. 10th World Congress on Endourology and ESWL, Singapore. September 1992
3. A Simple Database for Recording ESWL Results: Flannigan G*, Stewart P, Nargund V, Coombs L, Gray B, Doble A. 10th World Congress on Endourology/ ESWL, Singapore. September 1992
4. A New Culture Medium for Growing Bladder Cells in vitro: Nargund VH*, Barker IK, Flannigan GM, Stewart PAH, Crawford S M. Yorkshire Cancer Research Campaign- Annual Meeting: University of Hull, Hull. December 1992
5. Bladder Neck Incision- Which Position? Doble A*, Coombs L, Nargund V, Flannigan M, Stewart P. British Association of Urological Surgeons, Annual Meeting,Harrogate. June 1993
6. Differences between early passage cell lines and established cell lines- characterisation and growth studies. Nargund V H*, Barker I, Stewart PAH, Crawford SM. Audit and Research Group Meeting, Harrogate. November 1993
7. Audit of the Stoma Care in a District Hospital: Nargund VH, Watson M*, Ruddock KJ, Flannigan GM, Stewart PAH. The 10th Biennial Congress of the World Council of Enterostomal Therapists, Yokohama, Japan. June- July 1994
8. Effects of intravesical drugs on EGFr expression of established TCC cell lines. Nargund V*, Flannigan M, Stewart P A and Crawford S M. Presented at European Society of Medical Oncologists (ESMO) Annual Congress, Lisbon, Portugal. November 1994.
9. Telomerase activity in transitional cell carcinomas. Yoshida K, Sugino T, Nargund V, Tahara H, Boledeoku J, Woodman A, Toghe T and Tarin D*. 172nd Meeting of Pathological Society of Great Britain and Ireland, London UK. January 1996
10. Telomerase activity in transitional cell carcinoma: Its implications for non-invasive bladder cancer. Nargund V*, Yoshida K, Smith J C, Fellows G J, Cranston D W and Tarin D. British Association of Urological Surgeons. Annual meeting, Edinburgh. June 1996
11. Telomerase activity in transitional cell carcinoma: Its implications for non-invasive bladder cancer. Yoshida K*, Nargund V, Sugino T, Tahara H, Boledeoku J, Woodman A, Toghe T, Tarin D. T. 9th International Conference of Pathology, Pisa, Italy. Sept 1996
12. Haematuria: A long-term problem after prostatectomy. Nargund V*, Noble J, Cranston D, Fellows G. British Association of Urological Surgeons. Annual Meeting, Harrogate. June 1998
13. Chemotherapy ±Partial orchidectomy for testis conservation in patients with germ cell cancer (GCC): Is it safe, is it justified? Nargund V*, OliverT, Baithun S, Ong J, Sohab A, Reznek R, Badenoch D, Paris AMI. British Association of Urological Surgeons. Annual Meeting, Harrogate. June 1998
14. Prostate cancer imaging with Indium-111 labelled monoclonal antibody to prostate membrane specific antigen (PMSA). Fenely MR*, Jan H, Granowska M, Mather SJ, Ellison D, Oliver RT , Badenoch DF, Chinegwundoh FC, Nargund VH, Paris AMI, Britton KE. British Association of Urological Surgeons. Annual Meeting, Harrogate. June 1998
15. Bladder sparing with synchronous combination chemo/radiotherapy in invasive bladder cancer. Mulatero C W*, Bozcuk H s, Oliver R T D, Mair G, Nargund V H. 23rd European Society of Medical Oncologists Annual Congress, Athens, Greece. 1998
16. Testicular Seminoma diagnosed by annual ultrasound surveillance for testicular microlithiasis. Otite U*, Nambirajan T, Berney D M, Badenoch D F and Nargund V H. Clinico-pathological Meeting Royal Society of Medicine . Januay 2000
17. Antegrade JJ-Stenting in malignant ureteric obstruction still ahs a role: Otite U*, Dacie J, Chan L, Nambirajan T, Maheshkumar and Nargund V H. XV Congress of the European Association of Urology Meeting, Brussels, Belgium. April 2000
18. Testicular Microlithiasis: A Benign Condition with a malignant association or simply a pre-malignant condition?" Otite U*, Nambirajan T, Chan L, Webb J, Badenoch D, Hendry W, Nargund V. American Urological Association (Annual Meeting). April 2000
19. A comparison of Power and Colour Doppler in TRUS of the prostate- Otite U*, Nambirajan T, Chan L, Kumar M, Stewart E, Nargund V. British Association of Urological Surgeons, Birmingham. June 2000
20. Testicular Microlithiasis: A Benign Condition or a premalignant condition?" Otite U*, Nambirajan T, Chan L, Webb JW, Badenoch D F, Hendry W F, Nargund V H. British Association of Urological Surgeons. June 2000
21. Lysosomal associated membrane proteins in the assessment of basement mambrane invasion in superficial transitional carcinoma of the bladder. Mahesh Kumar*, J Martin, V H Nargund, Burney D. British Association of Urological Surgeons. June 2000
22. Dose intensification (q10 vs. q21/28) of chemotherapy and synchronous chemo/ radiation as strategies to improve bladder cancer outcome. T Oliver, T Goonewardene, G Mair, C Boshoff, R Ravi, J Hill. M Singh, C Fowler, V Nargund, T Philp. British Association of Urological Surgeons, June 2000
23. Expression of transforming growth factor receptors type 1 and type2 in superficial transitional cell carcinoma of the bladder. Mahesh Kumar*, J Martin, V H Nargund, Burney D. British Association of Cancer Research. Annual Meeting. June 2000
24. Cyclooxygenase2 expression in superficial TCC bladder. M. Kumar*, J Martin, V Nargund, Berney D. British Association of Cancer Research. Annual Meeting. June 2000
25. A comparison of power and colour Doppler in transrectal ultrasound of the prostate. Otite U, Chan L, Mahesh Kumar, Nargund V H*. European Society of Urogenital Radiology (ESUR 2000). London. Sept 2000
26. Percutaneous Antegrade Ureteric Stenting is still an effective treatment for malignant ureteric obstruction. Otite U*, Dacie J, Chan L, Nambirajan T, Kumar M, Nargund V. European Society of Urogenital Radiology, London. September 2000
27. Testicular Microlithiasis: A Benign Condition or a premalignant condition?" Otite U, Nambirajan T, Chan L, Webb J, Badenoch D, Hendry W, Nargund V*. European Society of Uro-genital Radiology (ESUR 2000), London September 2000
28. Evaluation of testicular blood flow and inhibin-B levels in the assessment of spermatogenic activity in normal and infertile men. S J Gordon*, V H Nargund. Urological Research Society, London. January 2000
29. Role of cycloxygenase 2 in superficial TCC bladder. M Kumar, Martin J, Otite U, Gordon S, Nargund V, Berney D. European Association of Urology Geneva. March 2001, 30. New radio-labelled monoclonal antibody Tc-99m J591 against the external domain of prostate specific membrane antigen in the management of prostate cancer. Gordon S, Otite U, Bharadwa J, Mather S J, Bander N, Canizales A, Britton K E, Nargund V H*. European Organisation for Research and Treatment of Cancer(EORTC), Geneva, February 2001
31. Detection of serum and urinary beta human chorionic gonadotrophin (hCGb) by immunoradiometric assay and enzyme-linked immunosorbent assay: Is this a useful marker for the clinical management of prostate cancer? Otite U, Iles R k, Jacoby E, Sheaff M, Chinegwundoh F C, Nargund V H, Baithun S. 18th European Congress of Pathology, Berlin, Germany. Sept 2001
32. Aminoterminal propeptide of type I procollagen is a useful marker in the clinical management of prostate cancer. Iles R, Otite U, Jefferson K, Jahnke U, Sheaff M, Nargund V H, Chinegwundoh F, Persad R, Baithun S. 18th European Congress of Pathology, Berlin Germany. September 2001
33. Tamsulosin in the management of patients in acute urinary retention due to BPH. Lucas M, Stephenson T, Nargund V H*. Presented in European Association of Urology, Birmingham 2002
34. Britton K E*, Gordon S J, Canizales A, Otite U, Mather S J, Ellison D, Elnaas S, Jan H, Bander N H, Nargund V H. Prostate cancer imaging with 99Tcm-J591 monoclonal antibody against prostate specific membrane antigen. 29th Annual Meeting, British Nuclear Medicine Society, Brighton. 2001
35. Lucas M*, Stephenson T and Nargund V. Tamsulosin reduces the need for recatheterisation in elderly male patients with a subsequent episode of acute urinary retention due to benign prostatic hyperplasia. 100th American Urological Association, Orlando, USA. May 2002
36. Gordon S*, Bharadwa J, Campbell S, Nargund V H. Relationship between testicular blood flow and infertility. British Association of Urological Surgeons, Glasgow 2003
37. Oliver RTD*, Berney D and Nargund VH. Testis conserving chemotherapy in Germ Cell Cancer: Its potential to increase understanding of the biology and treatment of carcinoma in situ. British Oncological association (BOA), Brighton. 2002
38. Bhardwa J, Maheshkumar P, Berney D, Martin JE, Nargund VH. Gene expression profiling of superficial bladder cancer using DNA chip technology. British Urological Society meeting, London. January 2003.
39. Gordon S J*, Campbell SC, Nargund VH. Testicular arterial blood flow as a marker of spermatogenesis. Annual meeting, American Urological Association, San Francisco, 2004
40. Nargund VH*, Al-Hashimi D, Kumar P, Gordon S, Otite U, Ellison D, Carroll M, Britton K. Imaging with radiolabelled monoclonal antibody specific for extracellar domain of prostate specific membrane antigen (PSMA) in staging prostate carcinoma for patients undergoing radical prostatectomy. Annual meeting, American Urological Association May 2004
41. Priya Kumar*, Bharadwa JM, Kapoor S, Nargund V H. Treatment of anastomotic strictures following RRP: An alternative approach using balloon dilatation. 27th Congress of Société Internationale d’Urologie Honolulu, Hawaii. October 2004,
42. Priya Kumar, Nargund V H. Samuel Pepys: A Patient. 27th Congress of Société Internationale d’Urologie Honolulu, Hawaii. October 2004,
43. Bhardwa J M, Sahadev A, Chew S, Oliver R T D and Nargund V H. Natural history of renal lesions in von Hippel-Lindau (VHL) disease: A single centre experience. British Association of Urological surgeons (Oncology section) , Edinburgh. November 2005
44. Kumar P, Baithun S, Oliver RTD, Pati J, Nargund VH. Lymphangiogenesis in germ cell tumours of the testis. Society for Basic Urologic Research. Miami,USA. December 2005
45. Priya Kumar, Baithun S, Oliver R T D, Nargund V H. Angiogenesis and lymphangiogenesis in Testicular Germ Cell Tumours. Pathological Society of Great Britain and Ireland. Winter Meeting, Robinson College & University of Cambridge, Cambridge: January 2006
46.Nora Brennan*, Khurshid Ghani, Vinod Nargund. Modernising Urological Training - A Nationwide Survey. BAUS Annual Meeting 2006, Manchester
47. Bose P*, Kumar P, Nargund V, Pati J. Reasons for not attending Outpatient Clinic. BAUS Annual Meeting 2006, Manchester
48. Priya Kumar*, Baithun S, Oliver R T D, Nargund V H. Angiogenesis and lymphangiogenesis in Testicular
Germ Cell Tumours. BAUS Annual Meeting 2006, Manchester
Professional Membership
American Urological Association (AUA) 1999-
British Association for Cancer Research (BACR) 1992-
British Association of Urological Surgeons (BAUS) 1988-
British Association of Urological Surgeons- Endourology Section 2005-
British Association of Urological Surgeons: Oncology Section 1997-
British Medical Association (BMA) 1995-
European Association of Urology (EAU) 1994-
European Organisation for Research and Treatment of Cancer (EORTC) 1999-
